DR6 Activators
DR6 activators form a diverse class of chemicals intricately modulating the signaling pathways governed by Death Receptor 6 (DR6), focusing on cellular responses related to survival, apoptosis, and inflammation. Anisomycin, a protein synthesis inhibitor, indirectly activates DR6 by inducing cellular stress and promoting the upregulation of DR6 through JNK signaling. The specificity of Anisomycin for JNK-mediated activation provides valuable insights into the intricate interplay between stress response pathways and DR6 modulation.
Forskolin, an adenylate cyclase activator, indirectly influences DR6 activity by elevating cAMP levels and stimulating the cAMP/PKA pathway. The altered activation state of DR6 induced by Forskolin influences its involvement in cellular processes related to neuronal development and apoptosis. Calyculin A, a protein phosphatase inhibitor, indirectly activates DR6 by influencing MAPK signaling. The altered phosphorylation patterns of DR6 induced by Calyculin A influence its role in cellular processes related to cell survival and apoptosis. DR6 activation is also influenced by PKC modulators, such as TPA and PMA, which indirectly activate DR6 by modulating PKC signaling. These compounds shed light on the intricate interplay between PKC activation and DR6-mediated cellular responses. Additionally, SB202190, a p38 MAP kinase inhibitor, serves as an indirect activator by disrupting the negative regulation imposed on DR6 signaling, providing insights into the interconnected signaling pathways governing DR6-mediated cellular responses. The specificity of these activators for key components like JNK, PKC, p38 MAP kinase, and MAPK highlights their role as targeted modulators, offering a nuanced understanding of DR6-mediated cellular responses to diverse physiological cues.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin, a potent protein synthesis inhibitor, indirectly activates DR6. By inducing cellular stress and activating the JNK pathway, Anisomycin leads to the upregulation of DR6 expression. The activation of DR6 in response to JNK signaling influences downstream events related to cell survival and apoptosis. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin, an adenylate cyclase activator, indirectly influences DR6 activity by elevating cAMP levels. By stimulating the cAMP/PKA pathway, Forskolin modulates downstream signaling events that intersect with DR6-regulated pathways. The altered activation state of DR6 induced by Forskolin influences its involvement in cellular processes related to neuronal development and apoptosis. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Calyculin A, a potent protein phosphatase inhibitor, indirectly activates DR6 by influencing MAPK signaling. By inhibiting protein phosphatases, Calyculin A enhances MAPK phosphorylation, leading to downstream effects on DR6-regulated pathways. The altered phosphorylation patterns of DR6 induced by Calyculin A influence its role in cellular processes related to cell survival and apoptosis. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA, a PKC activator, indirectly influences DR6 activity by modulating PKC signaling. By activating PKC, PMA modulates downstream signaling events that intersect with DR6-regulated pathways. | ||||||
SB202190 hydrochloride | 350228-36-3 | sc-222294 sc-222294A | 1 mg 5 mg | $131.00 $505.00 | 13 | |
SB202190, a p38 MAP kinase inhibitor, can act as an indirect activator of DR6. By inhibiting p38 MAP kinase, SB202190 disrupts the negative regulation imposed on DR6 signaling, leading to increased DR6 activation. The altered phosphorylation patterns of DR6 induced by SB202190 influence its role in cellular processes related to inflammation and apoptosis. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
Indirubin-3'-monoxime, a CDK inhibitor, indirectly influences DR6 activity by modulating cell cycle progression. By inhibiting CDKs, Indirubin-3'-monoxime disrupts downstream events related to DR6-regulated pathways. The altered activation state of DR6 induced by Indirubin-3'-monoxime influences its involvement in cellular processes related to cell survival and apoptosis. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic Acid, a potent protein phosphatase inhibitor, indirectly activates DR6 by influencing MAPK signaling. By inhibiting protein phosphatases, Okadaic Acid enhances MAPK phosphorylation, leading to downstream effects on DR6-regulated pathways. The altered phosphorylation patterns of DR6 induced by Okadaic Acid influence its involvement in cellular processes related to cell survival and apoptosis. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082, an inhibitor of NF-κB activation, can act as an indirect activator of DR6. By suppressing NF-κB activation, BAY 11-7082 disrupts the negative regulation imposed on DR6 signaling, leading to increased DR6 activation. The altered phosphorylation patterns of DR6 induced by BAY 11-7082 influence its role in cellular processes related to inflammation and apoptosis. | ||||||